| Patents for A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964) |
|---|
| 09/09/2005 | CA2546853A1 Use of interfering rna in the production of transgenic animals |
| 09/08/2005 | US20050197497 Used to improve the therapeutic efficacy of current cancer treatment; sensitizing cancerous cells to treatment with conventional anti-tumor drugs |
| 09/08/2005 | US20050197313 Multiple promoter expression cassettes for simultaneous delivery of RNAi agents |
| 09/08/2005 | US20050197312 Transcription factor RNA interference reagents and methods of use thereof |
| 09/08/2005 | US20050197310 TGaseII polypeptide antibodies; pulmonary, kidney, liver or ocular fibrosis; cardiac hypertrophy, atherosclerosis, restenosis; Alzheimer's and Parkinson's disease |
| 09/08/2005 | US20050197309 Antisense modulation of dual specific phosphatase 5 expression |
| 09/08/2005 | US20050197306 DNA vaccines encoding heat shock proteins |
| 09/08/2005 | US20050197305 Methods and compositions for blocking progression of a disease state |
| 09/08/2005 | US20050197304 Stimulating regeneration with naked DNA encoding bioactive agents; does not cause insertional mutagenesis, host immunogenicity or tissues targeting difficulties |
| 09/08/2005 | US20050196862 DNA cassette for cellular expression of small RNA |
| 09/08/2005 | US20050196860 Novel EPS8 compounds for therapy and diagnosis and methods for using same |
| 09/08/2005 | US20050196837 DNA construct comprising centromeric, telomeric and genomic regions for use in transfer of heterologous sequences into cells |
| 09/08/2005 | US20050196798 Nucleoside triphosphate diphosphohydrolase (NTPDASE 8) and uses thereof |
| 09/08/2005 | US20050196793 Using aberrant expression of caudal type homeobox transcription factor 2 (CDX2) as diagnostic indicator of stomach or esophageal cell proliferative disorers |
| 09/08/2005 | US20050196787 Antisense agents for use in treatment of diabetes and controlling blood lipid levels; gene expression inhibition |
| 09/08/2005 | US20050196781 RNA interference mediated inhibition of STAT3 gene expression using short interfering nucleic acid (siNA) |
| 09/08/2005 | US20050196765 siNA molecule comprising a double-stranded structure that down-regulates expression of checkpoint Kinase-1 (CHK-1), wherein said siNA molecule does not require the presence of nucleotides having a 2'-hydroxy group within the siNA molecule for mediating RNA interference |
| 09/08/2005 | US20050196751 Receptor protein is capable of activating transcription of desired gene when in presence of agonist and when bound to antagonist; gene therapy; gene expression inhibition; transgenic cells, animals |
| 09/08/2005 | US20050196443 Pulsatile release compositions and methods for enhanced intestinal drug absorption |
| 09/08/2005 | US20050196440 Mucoadhesive drug delivery devices and methods of making and using thereof |
| 09/08/2005 | US20050196416 Dispersions prepared by use of self-stabilizing agents |
| 09/08/2005 | US20050196391 Method and composition for inhibiting cancer cell growth |
| 09/08/2005 | US20050196384 Deliver a heterologous nucleic acid sequence in prime-boost vaccination regimens; sequence encodes the same gene product or antigen in the recombinant adenovirus vector of the first and second serotype; viral antigens are Ebola, measles, West Nile, HIV, SIV; cross neutralization not an issue |
| 09/08/2005 | US20050196383 Novel adjuvant system reduces risk of toxic side effects; based on honey bee venom melittin; oligonucleotide complexed or covalently linked with immunostimulatory peptide; non toxic DNA and RNA sequences to stimulate reactions against specific antigens, without risk of systemic immunogenicity, toxicity |
| 09/08/2005 | US20050196382 Administering an oligonucleotide at least 10 nucleotides in length, whose antiviral activity occurs principally by a non-sequence complementary mode of action; especially for the prophylaxis treatment of cancer caused by oncoviruses |
| 09/08/2005 | US20050196381 Lentivirus vector-based approaches for generating an immune response to HIV in humans |
| 09/07/2005 | EP1571157A1 LIPIN1 function |
| 09/07/2005 | EP1570067A2 Methods and compositions for immunization against hiv |
| 09/07/2005 | EP1569962A2 Regulatory elements in the 5' region of the vr1 gene |
| 09/07/2005 | EP1569696A2 Methods and immune modulatory nucleic acid compositions for preventing and treating disease |
| 09/07/2005 | EP1569695A2 Antisense modulation of apolipoprotein b expression |
| 09/07/2005 | EP1569662A2 Treatment of neurodegenerative disease through intracranial delivery of short interfering rna (sirna) |
| 09/07/2005 | EP1569658A2 Treatment of ebv and khsv infection and associated abnormal cellular proliferation |
| 09/07/2005 | EP1432432A4 A cancer treatment system |
| 09/07/2005 | EP1246642B1 Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization |
| 09/07/2005 | EP1073456B1 Use of osteoprotegerin for the prevention and treatment of cardiovascular diseases |
| 09/07/2005 | EP1025237B1 Human checkpoint kinase, hcds1, compositions and methods |
| 09/07/2005 | EP0876492B1 Novel methods for the characterization of compounds which stimulate stf-1 expression in pancreatic islet cells |
| 09/07/2005 | CN1665933A Immunoconjugates for the treatment of tumours |
| 09/07/2005 | CN1665932A Vectors with modified protease-dependent tropism |
| 09/07/2005 | CN1665929A Circular dumbbell decoy oligodeoxynucleotides (CDODN) containing DNA bindings sites of transcription |
| 09/07/2005 | CN1665927A Tumor-lysing virus growing selectively in tumor cells |
| 09/07/2005 | CN1665921A Adenovirus vectors for immunotherapy |
| 09/07/2005 | CN1665835A DNA sequence and recombinant production of the grass pollen allergen Phl p4 |
| 09/07/2005 | CN1665544A Drug- or gene-carrier composition having lowered hemagglutinin activity |
| 09/07/2005 | CN1665543A Fusions of cytokines and tumor targeting proteins |
| 09/07/2005 | CN1665534A Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 09/07/2005 | CN1665531A Cancer vaccines and methods of using the same |
| 09/07/2005 | CN1665529A Method to enhance an immune response of nucleic acid vaccination |
| 09/07/2005 | CN1665526A Novel tissue factor targeted thrombomodulin fusion proteins as anticoagulants |
| 09/07/2005 | CN1665391A Methods of expressing LIM mineralization protein in non-osseous cells |
| 09/07/2005 | CN1664100A Human antibody heavy chain and light chain variable region gene against SARS-Cov S antigen and polypeptide and use thereof |
| 09/07/2005 | CN1663616A Rotavirus gene vaccine based on NSP4 gene |
| 09/07/2005 | CN1663561A Use of rare earth element salt in preparation of insulin beta cell for treating diabetes |
| 09/06/2005 | US6939862 Method for transferring nucleic acid into striated muscles |
| 09/06/2005 | US6939851 Serine proteinase inhibitors |
| 09/06/2005 | US6939712 for expression inhibition/knockout of collagen, tumor necrosis factor, tat genes/proteins, and immunoglobulins |
| 09/06/2005 | US6939562 Collagen/polysaccharide bilayer matrix |
| 09/06/2005 | US6939544 Antibodies against mouse pituitary tumor transforming gene carboxy-terminal (PTTG-C) peptides |
| 09/06/2005 | US6939541 Polypeptide for use in the treatment of viral diseases and cancer |
| 09/06/2005 | US6939540 nucleic acid encoding an angiogenic protein is administered to a cell in a region of a bone such that the nucleic acid is expressed to produce the angiogenic protein, whereby bone density or formation is enhanced within the region |
| 09/06/2005 | CA2267760C Stent lining |
| 09/06/2005 | CA2160034C Gibbon ape leukemia virus-based retroviral vectors |
| 09/06/2005 | CA2105652C Reducing wound scarring with antibodies to growth factors |
| 09/03/2005 | CA2457303A1 Transductin-1 and transductin-2 and applications to hereditary deafness |
| 09/02/2005 | WO2004073646A2 Treatment of pain through expression of opioid receptors |
| 09/02/2005 | CA2555996A1 Treatment of pain through expression of opioid receptors |
| 09/01/2005 | WO2005080581A2 Insulated herpesvirus-derived gene expression cassettes for sustained and regulatable gene expression |
| 09/01/2005 | WO2005080573A1 Recombinant viral vectors to promote neuronal cell survival and uses thereof |
| 09/01/2005 | WO2005080568A1 Methods and compositions for treatment or prevention of secondary ischemic injury |
| 09/01/2005 | WO2005080567A1 Substituted, non-coding nucleic acid molecule used for the therapeutic and prophylactic immune stimulation in humans and higher animals |
| 09/01/2005 | WO2005080410A1 Targeted delivery of rna interference molecules for the treatment of ige-mediated disorders |
| 09/01/2005 | WO2005080409A1 Vectors having both isoforms of beta-hexosaminidase and uses of the same |
| 09/01/2005 | WO2005079859A1 Target directional carrier |
| 09/01/2005 | WO2005079848A2 Agonists and antagonists of p28 ebi3 and wsx/tccr for treating immune disorders |
| 09/01/2005 | WO2005079844A2 Use for interleukin-33 (il33) and the il-33 receptor complex |
| 09/01/2005 | WO2005079837A1 Methods of modulating il-23 activity; related reagents |
| 09/01/2005 | WO2005079836A1 Method for treating glaucoma |
| 09/01/2005 | WO2005079833A1 T cell immune response inhibitor |
| 09/01/2005 | WO2005079829A2 Method for treating glaucoma |
| 09/01/2005 | WO2005079815A2 Methods and reagents for treating autosomal dominant diseases of the eye |
| 09/01/2005 | WO2005079506A2 Systemic immune activation method using nucleic acid-lipid complexes |
| 09/01/2005 | WO2005079271A2 Combined immunotherapy of fusion cells and interleukin-12 for treatment of cancer |
| 09/01/2005 | WO2005079267A2 Methods for protein production |
| 09/01/2005 | WO2005040187A3 The use of sirna silencing in the prevention of metastasis |
| 09/01/2005 | WO2005033314A3 Method for the production of a cell and/or tissue and/or disease phase specific medicament |
| 09/01/2005 | WO2005026253A3 Labile linkage for compound delivery to a cell |
| 09/01/2005 | WO2005002504A3 Protection against vertical transmission of pathogenic infections |
| 09/01/2005 | WO2004099387A3 siRNA INDUCED SYSTEMIC GENE SILENCING IN MAMMALIAN SYSTEMS |
| 09/01/2005 | WO2004076639A8 Use of gene expression profiling in the diagnosis and treatment of lupus nephritis and systemic lupus erythematosus |
| 09/01/2005 | WO2004048512A3 Novel proteins and nucleic acids encoding same |
| 09/01/2005 | US20050192637 Method and apparatus for device controlled gene expression |
| 09/01/2005 | US20050192242 Therapeutic fusion protein transgenes |
| 09/01/2005 | US20050192241 Administering to the joint having systemic onset juvenile idiopathic arthritis an active agent that will reduce the bioavailability of interleukin-1 beta (IL-1 beta) by modifying the transcription, translation or gene expression or by blocking the IL-1 beta recepter;antiinflammatory agent; antipyretics |
| 09/01/2005 | US20050192240 Methods and compositions relating to expression factors |
| 09/01/2005 | US20050192239 Methods for identifying risk of breast cancer and treatments thereof |
| 09/01/2005 | US20050192238 Modulation of the expression of genes dependent on stat-1 |
| 09/01/2005 | US20050192219 Therapies involving mutated heat shock transcription factor |
| 09/01/2005 | US20050191747 Recombinant bovine immunodeficiency virus based gene transfer system |
| 09/01/2005 | US20050191746 Compositions and methods for biodegradable polymer-peptide mediated transfection |